Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

11 Sept 2019

Abstract excerpt

Ninety-seven percent of drug-indication pairs that are tested in clinical trials in oncology never advance to receive U.S. Food and Drug Administration approval. While lack of efficacy and dose-limiting toxicities are the most common causes of trial failure, the reason(s) why so many new drugs encounter these problems is not well understood. Using CRISPR-Cas9 mutagenesis, we investigated a set of cancer drugs and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to CRISPR and Genetic Engineering
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31511426
DOI: 10.1126/scitranslmed.aaw8412

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trialsPMID 31511426Read ↗

Pharmacogenomic discovery of genetically targeted cancer therapies optimized against clinical outcomesSemantic proximity Read ↗

Challenges and opportunities for drug repurposing in cancers based on synthetic lethality induced by tumor suppressor gene mutationsSemantic proximity Read ↗

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeuticsSemantic proximity Read ↗

Identifying chemogenetic interactions from CRISPR knockout screens with drugZSemantic proximity Read ↗

A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeuticsSemantic proximity Read ↗

Cancer drugs are closing in on some of the deadliest mutations.Semantic proximity Read ↗

A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivoSemantic proximity Read ↗

Genome-wide functional CRISPR screen reveals CDK7 as a targetable therapeutic vulnerability for head and neck cancerSemantic proximity Read ↗

DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets.Semantic proximity Read ↗

Identifying chemogenetic interactions from CRISPR screens with drugZSemantic proximity Read ↗

High-throughput CRISPR-mediated 3D enrichment platform for functional interrogation of chemotherapeutic resistanceSemantic proximity Read ↗

Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.